This page includes Regulatory news filings supplied by issuers listed on the BSX. Please note the BSX is not responsible for the content, accuracy or completeness of announcements filed by issuers and disclaims all liability for any loss arising from reliance on information contained within issuer announcements.

ImuMed Issues Statement

17 April 2001

Hamilton, Bermuda: 17 April, 2001- The Directors of ImuMed International Ltd. have today announced that ImuMed Deutschland GmbH (Antitoxin), together with its subsidiaries, Antitoxin Dr. Helmbold GmbH, Institut fur Immuntherapie Antitoxin Verwaltungs GmbH and Institut fur Immuntherapie Antitoxin GmbH & Co. KG have filed for bankruptcy protection in Germany.

Mr. Michael Reford has been appointed by the Board as an Interim Chairman and will be responsible for the filings on behalf of ImuMed International Ltd.